About AstronauTx

AstronauTx develops small molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company targets disrupted sleep architecture to amplify the brain's physiological protective mechanisms. This addresses a fundamental problem where abnormal sleep patterns accelerate cognitive decline and disease progression. The therapeutics restore dysregulated sleep physiology, correcting sleep architecture that supports brain health. This benefits people with Alzheimer's and related conditions, offering a novel pathway to slow disease advancement. Founded in 2019 as a UCL spinout, AstronauTx collaborates with leading scientists and contract research organisations to progress its portfolio into clinical studies.